md-medicaldata

Authors

 

Aneta Agić¹, Davor Korčok¹, Biljana Lazovic<sup>2

1</sup>Abela Pharm, Belgrade, Serbia,
²Clinical Hospital Center Zemun, Belgrade, Serbia

 

Rad je primljen 27.08.2017. / Prihvaćen 11.12.2017.

 

Correspondence to

Dr sci. med. Biljana Lazović,
KBC „Zemun“, Ul. Vukova 9, 11 000 Beograd
Telefon: +381 62 212 040
e-mail: lazovic.biljana@gmail.com

 

 

Abstract

 

Introduction and aim: Herbal expectorants and secretolytic agents hold a sizeable share of the European market. Therefore it is essential to test their clinical effectiveness and safety. It has been know from centuries that herbal products have long been recognized to have an important role in natural defense of respiratory disease from various exogenous toxins. In order to clarify the possible role of N-acetylcysteine (NAC) in the treatment of acute respiratory infections or exacerbations of chronics ones, we have carried out a study to assess the efficiency and safety of PropoMucil® in patients with various respiratory disease.
Matherial and method: The study was conducted from December 2016 to March 2017 in Belgrade, Serbia in five health care centers. The study included 904 patients suffered from various respiratory disease. All patients receivved natural products N-acetylcysteine combined with propolis to their additional therapy. We followed their symptoms on day 7th, 14th and after month ago.
Results: On the basis of the present assays, N-acetylcysteine combined with propolis (Propomucil®) have shown reduction of cough and mucus secretions in more than half patients on 7th day of usage of therapy. More than half patients (67,5%), on the 7th day check up had improvement in sputum production and its relieved. After a month of therapy with Propomucil®, only 7% have problems with persistent cough.
Conclusion: The study contributed to the evaluation of phytotherapy as a therapy of choice for relieve respiratory symptoms and its prevention. Results from our study have shown immense benefit (by reducing cough and dilution of sputum) of usage PropoMucil® in various respiratory disease.

 

 

 

Key words:

mucus, cough, mucociliary clearance, secretolytic agents, pharmacological effect.

 

 

Sažetak

 

Uvod: Biljni ekspektoransi i sekretolitički agensi imaju značajan udeo u evropskom tržištu. Zbog toga je neophodno testirati njihovu kliničku efikasnost i sigurnost. Od davnina je poznato da biljni proizvodi imaju protektivnu ulogu u respiratornom sistemu. Da bi se razjasnila moguća uloga N-acetilcisteina u lečenju akutnih respiratornih infekcija ili pogoršanja postojećih hroničnih, ovom studijom testirali smo efikasnost i sigurnost preparata Propomucil® u gore navedenim oboljenjima.
Materijal i metode: Studijom je obuhvaćeno ukupno 904 pacijenta koji su lečeni od različitih respiratornih oboljenja u 5 zdravstvenih centara u periodu od decembra 2016. godine do marta 2017. godine. Svaki pacijent je pored osnovne terapije dobio i dodatnu u vidu Propomucil®-a. Simptomi bolesti su praćeni nakon 7, 14 ili mesec dana terapije.
Rezultati: Smanjenje kašlja i mukozne sekrecije registrovano je već 7 dana od početka terapije kod više od pola ispitivanih pacijenata. Takođe, kod više od pola ispitivanih pacijenata (67,5%) pokazalo se poboljšanje u produkciji sputuma i njegovoj eliminaciji, pri čemu su se pacijenti značajno bolje osećali. Kod samo 7% pacijenata, nakon primenjene terapije, zadržao se kašalj.
Zaključak: Sprovedena studija doprinela je oceni fitoterapije kao terapije izbora za ublažavanje respiratornih simptoma. Rezultati naše studije pokazali su dobrobit (smanjenje kašlja i viskoznosti sputuma) upotrebom Propomucil®-a već 7.-og dana terapije kod obolelih od akutnih ili pogoršanja hroničnih respiratornih oboljenja.

 

 

Ključne reči:

sekret, kašalj, mukocilijarni klirens, sekretolitik, farmakološki efekti.

 

 

References

 

1. Shapiro DJ, Hicks LA, Pavia AT, Hersh AL. Antibiotic prescribing for adults in ambulatory care in the USA, 2007–09. J Antimicrob Chemother 2014;69:234-40.
2. Zaas AK, Garner BH, Tsalik EL, Burke T, Woods CW, et al. (2014) The current epidemiology and clinical decisions surrounding acute respiratory infections. Trends Mol Med 20: 579–588.
3. Schluger NW. Acute Respiratory Infections Atlas. New York, World Lung Foundation, 2010.
4. Septimus EJ, Albrecht HH, Solomon G, Shea T, Guenin EP.Extended-Release Guaifenesin/Pseudoephedrine Hydrochloride for Symptom Relief in Support of a Wait-and-See Approach for the Treatment of Acute Upper Respiratory Tract Infections: A Randomized, Double-Blind, Placebo-Controlled Study. Curr Ther Res Clin Exp. 2017; 84: 54-61.
5. Shapiro D, Bodinayake CK, Nagahawatte A, Devasiri V, Kurukulasooriya R, Hsiang J, Nicholson B, De Silva AD, Østbye T, Reller ME, Woods CW, Tillekeratne LG. Burden and Seasonality of Viral Acute Respiratory Tract Infections among Outpatients in Southern Sri Lanka. Am J Trop Med Hyg. 2017; 97(1):88-96
6. Gonzales R, Bartlett J, Besser R, Cooper  R, Hickner J, Hoffman J, Sande M. Principles of appropriate antibiotics use for treatment of acute respiratory tract infections in adults: Background, specific aims, and methods. Ann Intern Med. 2001; 134(6): 479-486.
7. McCullough AR, Pollack AJ, Plejdrup Hansen M, Glasziou PP, Looke DF, Britt HC, Del Mar CB. Antibiotics for acute respiratory infections in general practice: comparison of prescribing rates with guideline recommendations. Med J Aust. 2017; 207(2):65-69.
8. Millea PJ. N-Acetylcysteine: Multiple Clinical Applications. Am Fam Physician. 2009; 80(3): 265-269.
9. Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, Matera MG. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015; 24(137):451-61.
10. Ernst E, März R, Sieder C. A controlled multi-centre study of herbal versus synthetic secretolytic drugs for acute bronchitis. Phytomedicine.1997; 4(4): 287-93.
11. Kaschke O, Behrbohm H, Sydow K. The Influence of a Secretolytic Drug on Mucociliary Clearance of the Maxillary Sinus. Jour  of Rhinology 1997; 4(1): 29-33
12. Blesa S, Cortijo J, Mata M, Serrano A. et al. Oral N-acetylcysteine attenuates the pulmonary inflammatory response to antigen. Eur Respir J 2003; 21: 394-400.
13. Kang LJ, Lee HB, Bae HJ, Lee SG. Antidiabetic effect of propolis: reduction of expression of glucose-6-phosphatase through inhibition of Y279 and Y216 autophosphorylation of GSK-3α/β in HepG2 cells. Phytother Res. 2010; 24(10):1554-61.
14. Basnet P, Matsushige K, Hase K, Kadota S, Namba T: Four di-O-caffeoyl quinic acid derivatives from propolis. Potent hepatoprotective activity in experimental liver injury models. Biol Pharm Bull. 1996, 19: 1479-1484.
15. Mitamura T, Matsuno T, Sakamoto S, Maemura M, Kudo H, Suzuki S, Kuwa K, Yoshimura S, Sassa S, Nakayama T, Nagasawa H: Effects of a new clerodane diterpenoid isolated from propolis on chemically induced skin tumors in mice. Anticancer Res. 1996, 16: 2669-2672.
16. Christofidou-Solomidou M, Muzykantov VR. Antioxidant strategies in respiratory medicine. Treat Respir Med 2006; 5: 47-78. 15.
17. Cotgreave IA. N-Acetylcysteine: pharmacological consideration and experimental and clinical application. Adv Pharmacol 1997; 38: 205-227.
18. Sjodin K, Nilsson E, Hallberg A, Tunek A. Metabolism of N-acetyl-l-cysteine. Biochem Pharm 1989; 38: 3981-3985.
19. Brozmanova M, Hanacek J, Tatar M, Kollarik M. The influence of hyperoxia on cough reflex intensity in guinea pigs treated with bleomycin. Bratisl Lek Listy 2004; 105: 65-71. 12.
20. Brozmanova M, Hanacek J, Tatar M, Strapkova A, Szepe P. Effects of hyperoxia and allergic inflammation on cough reflex intensity in guinea pigs. Physiol Res 2002; 51: 529-536.
21. McNally JB, McCaughey WF, Standifer LN, Todd FE. Partition of excreted nitrogen from honey bees fed various proteins. J Nutr. 1965; 85: 113–116.

UDK: 616.2-022-085.322
615.322:582

PDF Agić A. et al • MD-Medical Data 2017;9(4): 213-218